Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Optimal aspirin dose in acute coronary syndromes: an emerging consensus.

DiNicolantonio JJ, Norgard NB, Meier P, Lavie CJ, O'Keefe JH, Niazi AK, Chatterjee S, Packard KA, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Bangalore S, Fuchs FD, Serebruany VL.

Future Cardiol. 2014 Mar;10(2):291-300. doi: 10.2217/fca.14.7. Review.

PMID:
24762255
3.

New antiplatelet agents in the treatment of acute coronary syndromes.

Sabouret P, Taiel-Sartral M.

Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11. Review.

4.

Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.

Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR; Canadian Cardiovascular Society.

Can J Cardiol. 2013 Nov;29(11):1334-45. doi: 10.1016/j.cjca.2013.07.001. Epub 2013 Aug 23. Review.

PMID:
23978596
5.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

6.

Antiplatelet options for secondary prevention in acute coronary syndromes.

Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1403-15. doi: 10.1586/erc.11.139. Review.

PMID:
22059790
7.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
8.
9.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
10.
11.

[Differentiated antiplatelet therapy for acute coronary syndromes].

Schäfer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S.

Dtsch Med Wochenschr. 2014 Jan;139(4):152-8. doi: 10.1055/s-0033-1359911. Epub 2014 Jan 15. Review. German.

PMID:
24430955
12.

Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G.

Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.

PMID:
21068525
13.

Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?

Varenhorst C, James S.

Curr Cardiol Rep. 2012 Aug;14(4):486-92. doi: 10.1007/s11886-012-0273-y. Review.

PMID:
22535473
14.

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.

[No authors listed]

Prescrire Int. 2009 Oct;18(103):193-5.

PMID:
19877380
15.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
16.

[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].

Schreiber P, Fauchère I, Wyss C.

Praxis (Bern 1994). 2014 Sep 3;103(18):1049-58. doi: 10.1024/1661-8157/a001762. Review. German. No abstract available.

PMID:
25183612
17.

Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.

Berger JS.

Am J Cardiol. 2013 Sep 1;112(5):737-45. doi: 10.1016/j.amjcard.2013.04.055. Epub 2013 Jun 7. Review.

PMID:
23751937
18.

[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].

Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.

Dtsch Med Wochenschr. 2011 Apr;136(15):782-5. doi: 10.1055/s-0031-1272567. Epub 2011 Mar 22. Review. German. No abstract available.

PMID:
21432747
19.

Emerging oral antiplatelet therapies for acute coronary syndromes.

Pollack CV Jr.

Hosp Pract (1995). 2010 Nov;38(4):29-37. doi: 10.3810/hp.2010.11.337.

PMID:
21068524
20.

Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.

Serebruany VL, DiNicolantonio JJ.

Thromb Haemost. 2013 Jul;110(1):5-10. doi: 10.1160/TH13-02-0142. Epub 2013 Jun 7.

PMID:
23743577

Supplemental Content

Support Center